Ann Childress, MD
Center for Psychiatry And Behavioral Medicine Inc. · Vector Clinical Trials · Principal Investigator
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ann Childress, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:59 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07169162 · ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity DisorderAytu BioPharma, Inc. · withdrawn · Attention Deficit Hyperactivity Disorder · principal investigator
- Ph4NCT07044609 · A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODDLas Vegas Medical Research, LLC DBA Vector Clinical Trials · not yet recruiting · Attention-deficit/Hyperactivity Disorder, Oppositional Defiant Disorder in Children · principal investigator
- Ph4NCT05721235 · A Safety/Tolerability and PK Study With Azstarys® in Children With ADHDCorium, Inc. · completed · Attention Deficit/Hyperactivity Disorder · principal investigator
- Ph4NCT05685732 · An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHDCorium, Inc. · completed · Attention Deficit/Hyperactivity Disorder · principal investigator
- Ph3NCT05631626 · Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.Cingulate Therapeutics · completed · ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined · principal investigator
- N/ANCT05296473 · Guided ADHD Therapy for Managing the Extent and Severity of SymptomsLumos Labs, Inc. · completed · ADHD · principal investigator
- Ph3NCT05286762 · Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301Cingulate Therapeutics · completed · ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type · study chair
- Ph3NCT03460652 · KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHDZevra Therapeutics · completed · ADHD · principal investigator
- Ph2NCT02884544 · A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHDIronshore Pharmaceuticals and Development, Inc · completed · Attention-Deficit Hyperactivity Disorder (ADHD) · principal investigator
- Ph4NCT02683265 · A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHDRhodes Pharmaceuticals, L.P. · completed · Attention Deficit Disorder With Hyperactivity · principal investigator
- Ph4NCT02677519 · A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHDRhodes Pharmaceuticals, L.P. · unknown · Attention Deficit Disorder With Hyperactivity · principal investigator
- Ph3NCT02493777 · A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom SettingIronshore Pharmaceuticals and Development, Inc · completed · Attention Deficit Hyperactivity Disorder · principal investigator
- Ph3NCT00141063 · Safety and Efficacy Study of Dexmethylphenidate in Children With ADHDNovartis · completed · ADHD · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.